# US 2024/0254087 A1 · Selective, partial, and arrestin-biased 5-ht2a agonists with utility in various disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0254087 A1
- Document ID: US20240254087A1
- Status: Published application
- Kind: A1
- Application number: 18/560,113
- Filed: 2022-05-11
- Published: 2024-08-01
- Earliest claimed: 2021-05-11
- Assignees: Saint Joseph's University; The Medical College of Wisconsin, Inc.; The Regents of the University of California
- Applicants: Saint Joseph's University; The Medical College of Wisconsin, Inc.; The Regents of the University of California
- Inventors: Jason WALLACH; John MCCORVY; Adam HALBERSTADT
- Web page: https://patentgrep.com/patent/US20240254087A1

## CPC

- C07D 215/12: with substituted hydrocarbon radicals attached to ring carbon atoms
- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 31/341: not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
- A61K 31/343: condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A61K 31/357: having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K 31/381: having five-membered rings
- A61K 31/415: 1,2-Diazoles
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/472: Non-condensed isoquinolines, e.g. papaverine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/24: Antidepressants
- A61P 25/26: Psychostimulants, e.g. nicotine, cocaine
- C07C 217/60: linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
- C07D 213/38: having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
- C07D 217/04: with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
- C07D 231/12: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 307/52: Radicals substituted by nitrogen atoms not forming part of a nitro radical
- C07D 307/91: Dibenzofurans; Hydrogenated dibenzofurans
- C07D 317/64: Oxygen atoms
- C07D 333/20: by nitrogen atoms (nitro, nitroso radicals C07D333/12)
- C07D 333/76: Dibenzothiophenes
- C07D 493/04: Ortho-condensed systems
- C07C 2602/02: the rings having only two atoms in common
- C07C 2602/08: the other ring being five-membered, e.g. indane
- C07C 2602/10: the other ring being six-membered, e.g. tetraline
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

Disclosed herein are novel serotonin 5-HT2A receptor agonists with selectivity for the 5-HT2A receptor subtype over other serotonin receptors. Some of these 5-HT2A agonists exhibit functional selectivity and preferentially activate arrestin signaling over G protein-mediated signaling. Also disclosed are pharmaceutical compositions of the compounds and methods of treating certain diseases or conditions.

## Claims

### Claim 1

A compound of formula (I) or a pharmaceutically acceptable salt thereof,
Wherein:
R1, R2, R3, R4 and R5 are independently selected from the group consisting of hydrogen, deuterium, OC1-6alkyl, SC1-6alkyl, CN, OH, halogen, NO2, N(Rm)2, C(O)ORm, C(O)N(Rm)2, C(O)C1-6alkyl, haloC1-6alkyl, haloC1-6alkyleneO, C1-6alkyl, hydroxyC1-6alkyl, dihydroxyC1-10alkyl, C3-6cycloalkyl, C(═NC1-6alkyl)C1-6alkyl, OC(O)N(Rm)2, SH, C(O)SRm, OC1-6alkyleneOC1-6alkyl, OC1-6alkyleneO-haloC1-6alkyl, SC1-6alkyleneOC1-6alkyl, SC1-6alkyleneSC1-6alkyl, OC1-6alkyleneSC1-6alkyl, SC1-6alkyleneO-haloC1-6alkyl, SC1-6alkyleneS-haloC1-6alkyl, OC1-6alkyleneS-haloC1-6alkyl, C1-6alkylene-CN, OC1-6alkylene-CN, SC1-6alkylene-CN, OC1-6alkylene-N(Rm)2, C2-6alkynyl, C2-6alkenyl, SO2N(Rm)2, NRmSO2C1-6alkyl, C1-6alkylSO2 (sulfone), S(O)OH, C1-6alkylS(O) (sulfoxide), nitroso, C1-6alkylOSO2, 3-10 membered heterocycloalkyl, 6-10 membered aryl, 5-10 membered heteroaryl, C1-6alkylene-N(Rm)2, C1-6alkylene-N(Rm)(CORm);
provided that at least one of R1 and R2 contains an oxygen bonded to the phenyl ring;
A is 4, 5, 6 or 7 membered ring optionally substituted with one or more substituents selected from the group consisting of OC1-6alkyl, SC1-6alkyl, CN, OH, halogen, NO2, N(Rm)2, C(O)ORm, C(O)N(Rm)2, C(O)C1-6alkyl, haloC1-6alkyl, haloC1-6alkyleneO, C1-6alkyl, hydroxyC1-6alkyl, dihydroxyC1-10alkyl, C(═NC1-6alkyl)C1-6alkyl, OC(O)N(Rm)2, SH, C(O)SRm, OC1-6alkyleneOC1-6alkyl, OC1-6alkyleneO-haloC1-6alkyl, SC1-6alkyleneOC1-6alkyl, SC1-6alkyleneSC1-6alkyl, OC1-6alkyleneSC1-6alkyl, SC1-6alkyleneO-haloC1-6alkyl, SC1-6alkyleneS-haloC1-6alkyl, OC1-6alkyleneS-haloC1-6alkyl, C1-6alkylene-CN, OC1-6alkylene-CN, SC1-6alkylene-CN, OC1-6alkylene-N(Rm)2, C2-6alkynyl, C2-6alkenyl, SO2N(Rm)2, NRmSO2C1-6alkyl, C1-6alkylSO2 (sulfone), S(O)OH, C1-6alkylS(O) (sulfoxide), nitroso, C1-6alkylOSO2, C3-6cycloalkyl, 3-10 membered heterocycloalkyl, 6-10 membered aryl, 5-10 membered heteroaryl, 5-12 membered bicycloalkyl, and 5-12 membered hetero-bicycloalkyl, wherein the C3-6cycloalkyl, 3-10 membered heterocycloalkyl, 6-10 membered aryl, 5-10 membered heteroaryl, 5-12 membered bicycloalkyl, 5-12 membered hetero-bicycloalkyl, O—C3-6cycloalkyl, O-heterocycloalkyl3-10-membered, O-aryl6-10-membered, O-heteroaryl5-10-membered, O-bicycloalkyl5-12-membered, O-hetero-bicycloalkyl5-12-membered, OC1-2alkylene-C3-6cycloalkyl, OC1-2alkylene-heterocycloalkyl3-10-membered, OC1-2alkylene-aryl6-10-membered, OC1-2alkylene-heteroaryl5-10-membered, OC1-2alkylene-bicycloalkyl5-12-membered, OC1-2alkylene-hetero-bicycloalkyl5-12-membered, C1-2alkylene-C3-6cycloalkyl, C1-2alkylene-heterocycloalkyl3-10-membered, C1-2alkylene-aryl6-10-membered, C1-2alkylene-heteroaryl5-10-membered, C1-2alkylene-bicycloalkyl5-12-membered, C1-2alkylene-hetero-bicycloalkyl5-12-membered, wherein each of these rings is optionally substituted with one or more substituents selected from the group consisting of OC1-6alkyl, SC1-6alkyl, CN, OH, halogen, NO2, N(Rm)2, C(O)ORm, C(O)N(Rm)2, C(O)C1-6alkyl, haloC1-6alkyl, haloC1-6alkyleneO, C1-6alkyl, hydroxyC1-6alkyl, C(=NC1-6alkyl)C1-6alkyl, OC(O)N(Rm)2, SH, C(O)SRm, OC1-6alkyleneOC1-6alkyl, OC1-6alkyleneO-haloC1-6alkyl, SC1-6alkyleneOC1-6alkyl, SC1-6alkyleneSC1-6alkyl, OC1-6alkyleneSC1-6alkyl, SC1-6alkyleneO-haloC1-6alkyl, SC1-6alkyleneS-haloC1-6alkyl, OC1-6alkyleneS-haloC1-6alkyl, C1-6alkylene-CN, OC1-6alkylene-CN, SC1-6alkylene-CN, OC1-6alkylene-N(Rm)2, C2-6alkynyl, C2-6alkenyl, SO2N(Rm)2, NRmSO2C1-6alkyl, C1-6alkylSO2 (sulfone), S(O)OH, C1-6alkylS(O) (sulfoxide), nitroso, and C1-6alkylOSO2;
alternatively, two adjacent substituents of A link up and together with A form a bicyclic or tricylic ring;
Rm each is independently hydrogen or C1-6alkyl or halo-C1-6alkyl;
L1 is C1-3alkylene, optionally R1 and L1 link up to form a ring; and
L2 is a bond or C1-3alkylene optionally substituted with C1-4alkyl, C3-6 cycloalkyl, haloC1-4alkyl, deuterium or F,
provided that the compound is not
wherein X is CN, Cl, Br or I.

### Claim 2 (depends on 1)

The compound of formula (I) or the pharmaceutically acceptable salt thereof of claim 1, wherein R1 is OC1-3alkyl.

### Claim 3 (depends on 1)

The compound of formula (I) or the pharmaceutically acceptable salt thereof of claim 1, wherein R2 is OC1-3alkyl.

### Claim 4 (depends on 1)

The compound of formula (I) or the pharmaceutically acceptable salt thereof of claim 1, wherein R4 is OC1-3alkyl.

### Claim 5 (depends on 1)

The compound of formula (I) or the pharmaceutically acceptable salt thereof of claim 1, wherein R6 is OC1-3alkyl.

### Claim 6 (depends on 1)

The compound of formula (I) or the pharmaceutically acceptable salt thereof of claim 1, wherein
(a) R1 and R4 are each independently OC1-3alkyl;
(b) R1 and R5 are each independently OC1-3alkyl; or
(c) R2 and R5 are each independently OC1-3alkyl.

### Claim 7 (depends on 1)

The compound of formula (I) or the pharmaceutically acceptable salt thereof of claim 1, wherein R3 is selected from the group consisting of OC1-6alkyl, SC1-6alkyl, CN, halogen, NO2, N(Rm)2, haloC1-6alkyl, and C1-6alkyl, and R4 is selected from the group consisting of hydrogen, OC1-6alkyl, SC1-6alkyl, CN, OH, halogen, NO2, N(Rm)2, haloC1-6alkyl, and C1-6alkyl.

### Claim 8 (depends on 1)

The compound of formula (I) or the pharmaceutically acceptable salt thereof of claim 1, wherein R1 and R4 are each independently OC1-3alkyl; R3 is NO2, haloC1-6alkyl, or C1-6alkyl.

### Claim 9 (depends on 1)

The compound of formula (I) or the pharmaceutically acceptable salt thereof of claim 1, wherein L1 is ethylene.

### Claim 10 (depends on 1)

The compound of formula (I) or the pharmaceutically acceptable salt thereof of claim 1, wherein L2 is methylene.

### Claim 11 (depends on 1)

The compound of formula (I) or the pharmaceutically acceptable salt thereof of claim 1, wherein two adjacent substituents of A link up and together with A form a bicyclic ring or tricyclic ring.

### Claim 12 (depends on 1)

The compound of formula (I) or the pharmaceutically acceptable salt thereof of claim 1, wherein two adjacent substituents of A link up and together with A form a bicyclic ring selected from the group consisting of indanyl, 1,2,3,4-tetrahydronaphthalenyl, benzimidazolyl, benzofuranyl, benzoselenophene, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolinyl, chromanyl, chromenyl, cinnolinyl, indolenyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, indazolyl, isobenzofuranyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, methylenedioxyphenyl, naphthyridinyl, naphthalenyl, octahydroisoquinolinyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, tetrahydroisoquinolinyl, and tetrahydroquinolinyl, wherein the bicyclic ring is optionally substituted with one or more substituents selected from the group consisting of OC1-6alkyl, SC1-6alkyl, CN, OH, halogen, NO2, N(Rm)2, C(O)ORm, C(O)N(Rm)2, C(O)C1-6alkyl, haloC1-6alkyl, haloC1-6alkyleneO, C1-6alkyl, hydroxyC1-6alkyl, and dihydroxyC1-10alkyl.

### Claim 13 (depends on 1)

The compound of formula (I) or the pharmaceutically acceptable salt thereof of claim 1, wherein A is represented as
Wherein R6 and R7 are independently selected from the group consisting of H, OC1-6alkyl, SC1-6alkyl, CN, OH, halogen, N(Rm)2, C(O)ORm, C(O)N(Rm)2, C(O)C1-6alkyl, haloC1-6alkyl, haloC1-6alkyleneO, C1-6alkyl, hydroxyC1-6alkyl, C(═NC1-6alkyl)C1-6alkyl, OC(O)N(Rm)2, SH, C(O)SRm, OC1-6alkyleneOC1-6alkyl, OC1-6alkyleneO-haloC1-6alkyl, SC1-6alkyleneOC1-6alkyl, SC1-6alkyleneSC1-6alkyl, OC1-6alkyleneSC1-6alkyl, SC1-6alkyleneO-haloC1-6alkyl, SC1-6alkyleneS-haloC1-6alkyl, OC1-6alkyleneS-haloC1-6alkyl, C1-6alkylene-CN, OC1-6alkylene-CN, SC1-6alkylene-CN, OC1-6alkylene-N(Rm)2, C2-6alkynyl, C2-6alkenyl, SO2N(Rm)2, NRmSO2C1-6alkyl, C1-6alkylSO2 (sulfone), S(O)OH, C1-6alkylS(O) (sulfoxide), nitroso, C1-6alkylOSO2, C3-6cycloalkyl, 3-10 membered heterocycloalkyl, 6-10 membered aryl, 5-10 membered heteroaryl, 5-12 membered bicycloalkyl, 5-12 membered hetero-bicycloalkyl, O—C3-6cycloalkyl, O-heterocycloalkyl3-10-membered, O-aryl6-10-membered, O-heteroaryl5-10-membered, O-bicycloalkyl5-12-membered, O-hetero-bicycloalkyl5-12-membered, OC1-2alkylene-C3-6cycloalkyl, OC1-2alkylene-heterocycloalkyl3-10-membered, OC1-2alkylene-aryl6-10-membered, OC1-2alkylene-heteroaryl5-10-membered, OC1-2alkylene-bicycloalkyl5-12-membered, OC1-2alkylene-hetero-bicycloalkyl5-12-membered, C1-2alkylene-C3-6cycloalkyl, C1-2alkylene-heterocycloalkyl3-10-membered, C1-2alkylene-aryl6-10-membered, C1-2alkylene-heteroaryl5-10-membered, C1-2alkylene-bicycloalkyl5-12-membered, and C1-2alkylene-hetero-bicycloalkyl5-12-membered, wherein each of the ring is optionally substituted; provided that at least one of R6 and R7 is not H;
R8, R9 and R10 are independently selected from the group consisting of H, OC1-6alkyl, SC1-6alkyl, CN, OH, halogen, N(Rm)2, C(O)ORm, C(O)N(Rm)2, C(O)C1-6alkyl, haloC1-6alkyl, haloC1-6alkyleneO, C1-6alkyl, hydroxyC1-6alkyl, C(═NC1-6alkyl)C1-6alkyl, OC(O)N(Rm)2, SH, C(O)SRm, OC1-6alkyleneOC1-6alkyl, OC1-6alkyleneO-haloC1-6alkyl, SC1-6alkyleneOC1-6alkyl, SC1-6alkyleneSC1-6alkyl, OC1-6alkyleneSC1-6alkyl, SC1-6alkyleneO-haloC1-6alkyl, SC1-6alkyleneS-haloC1-6alkyl, OC1-6alkyleneS-haloC1-6alkyl, C1-6alkylene-CN, OC1-6alkylene-CN, SC1-6alkylene-CN, OC1-6alkylene-N(Rm)2, C2-6alkynyl, C2-6alkenyl, SO2N(Rm)2, NRmSO2C1-6alkyl, C1-6alkylSO2 (sulfone), S(O)OH, C1-6alkylS(O) (sulfoxide), nitroso, and C1-6alkylOSO2.

### Claim 14 (depends on 13)

The compound of formula (I) or the pharmaceutically acceptable salt thereof of claim 13, wherein R6 is selected from the group consisting of C3-6cycloalkyl, 3-10 membered heterocycloalkyl, 6-10 membered aryl, 5-10 membered heteroaryl, 5-12 membered bicycloalkyl, 5-12 membered hetero-bicycloalkyl, O—C3-6cycloalkyl, O-heterocycloalkyl3-10-membered, O-aryl6-10-membered, O-heteroaryl5-10-membered, O-bicycloalkyl5-12-membered, O-hetero-bicycloalkyl5-12-membered, OC1-2alkylene-C3-6cycloalkyl, OC1-2alkylene-heterocycloalkyl3-10-membered, OC1-2alkylene-aryl6-10-membered, OC1-2alkylene-heteroaryl5-10-membered, OC1-2alkylene-bicycloalkyl5-12-membered, OC1-2alkylene-hetero-bicycloalkyl5-12-membered, C1-2alkylene-C3-6cycloalkyl, C1-2alkylene-heterocycloalkyl3-10-membered, C1-2alkylene-aryl6-10-membered, C1-2alkylene-heteroaryl5-10-membered, C1-2alkylene-bicycloalkyl5-12-membered, C1-2alkylene-hetero-bicycloalkyl5-12-membered, wherein each of the rings is optionally substituted.

### Claim 15 (depends on 13)

The compound of formula (I) or the pharmaceutically acceptable salt thereof of claim 13, wherein R6 is an optionally substituted ring system selected from the group consisting of adamantanyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, tetrahydrofuranyl, ferrocenyl, furanyl, furazanyl, imidazolinyl, imidazolyl, norbornyl, norbornenyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxazolidinyl, phenyl, piperazinyl, pyrimidinyl, piperonyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridinyl, pyridyl, pyrimidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, tetrazolyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl, triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl.

### Claim 16 (depends on 13)

The compound of formula (I) or the pharmaceutically acceptable salt thereof of claim 13, wherein R6 is selected from the group consisting of H, OC1-6alkyl, SC1-6alkyl, CN, OH, halogen, N(Rm)2, C(O)ORm), C(O)N(Rm)2, C(O)C1-6alkyl, haloC1-6alkyl, haloC1-6alkyleneO, C1-6alkyl, and hydroxyC1-6alkyl; and
R7 is selected from the group consisting of H, OC1-6alkyl, SC1-6alkyl, CN, OH, halogen, N(Rm)2, C(O)C1-6alkyl, haloC1-6alkyl, haloC1-6alkyleneO, C1-6alkyl, hydroxyC1-6alkyl, C3-6cycloalkyl, C3-6cycloalkyl, 3-10 membered heterocycloalkyl, 6-10 membered aryl, 5-10 membered heteroaryl, 5-12 membered bicycloalkyl, 5-12 membered hetero-bicycloalkyl, O—C3-6cycloalkyl, O-heterocycloalkyl3-10-membered, O-aryl6-10-membered, O-heteroaryl5-10-membered, O-bicycloalkyl5-12-membered, O-hetero-bicycloalkyl5-12-membered, OC1-2alkylene-C3-6cycloalkyl, OC1-2alkylene-heterocycloalkyl3-10-membered, OC1-2alkylene-aryl6-10-membered, OC1-2alkylene-heteroaryl5-10-membered, OC1-2alkylene-bicycloalkyl5-12-membered, OC1-2alkylene-hetero-bicycloalkyl5-12-membered, C1-2alkylene-C3-6cycloalkyl, C1-2alkylene-heterocycloalkyl3-10-membered, C1-2alkylene-aryl6-10-membered, C1-2alkylene-heteroaryl5-10-membered, C1-2alkylene-bicycloalkyl5-12-membered, C1-2alkylene-hetero-bicycloalkyl5-12-membered, wherein each of the ring is optionally substituted.

### Claim 17 (depends on 13)

The compound of formula (I) or the pharmaceutically acceptable salt thereof of claim 13, wherein R8 is selected from the group consisting of OC1-6alkyl, SC1-6alkyl, CN, OH, halogen, N(Rm)2, haloC1-6alkyl, haloC1-6alkyleneO, C1-6alkyl, C(═NC1-6alkyl)C1-6alkyl, OC(O)N(Rm)2, SH, C(O)SRm, OC1-6alkyleneOC1-6alkyl, OC1-6alkyleneO-haloC1-6alkyl, SC1-6alkyleneOC1-6alkyl, SC1-6alkyleneSC1-6alkyl, OC1-6alkyleneSC1-6alkyl, SC1-6alkyleneO-haloC1-6alkyl, SC1-6alkyleneS-haloC1-6alkyl, OC1-6alkyleneS-haloC1-6alkyl, C1-6alkylene-CN, OC1-6alkylene-CN, SC1-6alkylene-CN, OC1-6alkylene-N(R11)2, C2-6alkynyl, C2-6alkenyl, SO2N(Rm)2, NRmSO2C1-6alkyl, C1-6alkylSO2 (sulfone), S(O)OH, C1-6alkylS(O) (sulfoxide), nitroso, and C1-6alkylOSO2.

### Claim 18 (depends on 1)

The compound of formula (I) or the pharmaceutically acceptable salt thereof of claim 1, which is represented by
Wherein
Compound
R6
R7
R8
R10
R3
25N-NBOH
OH
H
H
H
NO2
(3)
25N-NBOMe
OCH3
H
H
H
NO2
(4)
25N-NBOEt
OCH2CH3
H
H
H
NO2
(5)
25N-NBMe
CH3
H
H
H
NO2
(6)
25N-NBF
F
H
H
H
NO2
(7)
25N-NBCl
Cl
H
H
H
NO2
(8)
25N-NBBr
Br
H
H
H
NO2
(9)
25N-NBI
I
H
H
H
NO2
(10)
25N-NBOCF2H
OCF2H
H
H
H
NO2
(11)
25N-NBOCF3
OCF3
H
H
H
NO2
(12)
25N-NBMDF2
OCF2O
H
H
NO2
(13)
25N-NBCF3
CF3
H
H
H
NO2
(14)
25N-NBNO2
NO2
H
H
H
NO2
(15)
25N-N-1-Nap
(CH)4
H
H
NO2
(16)
25N-NBPh
Ph
H
H
H
NO2
(17)
25N-NB-2-OH-3-Me
OH
CH3
H
H
NO2
(18)
25N-NB-2-MeO-3-F
OCH3
F
H
H
NO2
(19)
25N-NB-2,5-DiMeO
OCH3
H
H
OCH3
NO2
(20)
25N-NB-3-OH
H
OH
H
H
NO2
(21)
25N-NB-3-Me
H
CH3
H
H
NO2
(22)
25N-NB-4-Me
H
H
CH3
H
NO2
(23)
25N-NB-3-F
H
F
H
H
NO2
(24)
25N-NB-4-F
H
H
F
H
NO2
(25)
25D-NBOMe
OCH3
H
H
H
CH3
(26)
25D-N1-Nap
(CH)4
H
H
CH3
(27)
25D-NBPh
Ph
H
H
H
CH3
(28)

### Claim 19 (depends on 1)

A pharmaceutical composition comprising the compound of formula (I) or the pharmaceutically acceptable salt thereof of claim 1 and a pharmaceutically acceptable carrier.

### Claim 20 (depends on 1)

A method of treating a disease or condition, comprising administering to a subject in need thereof the compound of formula (I) or the pharmaceutically acceptable salt thereof of claim 1.

### Claim 21 (depends on 20)

The method of claim 20, wherein the disease or condition is a psychiatric or neurological disease or condition or sign or symptom selected from the group consisting of attention deficient disorder, attention deficit hyperactivity disorder (ADHD), adult attention-deficit/hyperactivity disorder, learning disorders, neurocognitive disorders, Tic disorders, autism spectrum disorder, Tourette's disorder, schizophrenia, negative symptoms of schizophrenia, cognitive symptoms of schizophrenia, substance/medication-induced psychotic disorder, psychotic disorder due to another medical condition, brief psychotic disorder, schizophreniform disorder, schizoaffective disorder, disruptive mood dysregulation disorder, depression, post-partum depression, persistent depressive disorder, major depressive episode, major depressive disorder, treatment-resistant depression, post-traumatic stress disorder, reactive attachment disorder, disinhibited social engagement disorder, personality disorders, psychopathy, cyclothymic disorder, manic episode, hypomanic episode, bipolar disorder, delusional disorder, obsessive compulsive disorder, hoarding disorder, premenstrual dysphoric disorder, somatic symptom and related disorders, intellectual disabilities, communication disorders, motor disorders, catalepsy, catatonia, agitation, hypertension, sleep disorders, sexual dysfunctions anxiety disorders, adjustment disorders, body dysmorphic disorder, Trichotillomania, excoriation disorder, substance/medication-induced obsessive-compulsive and related disorder, dementias, neurodegenerative diseases, seasonal affective disorder, pseudobulbar affect, cluster headache, headaches, migraines, Tension-type headaches, tinnitus, hallucinations, delusions, epilepsies, cyclic vomiting syndrome, cannabinoid hyperemesis, nausea, restless leg syndrome, weight loss or binge eating, anorexia nervosa, bulimia nervosa, alcoholism, nicotine dependence, substance use disorders, non-substance related disorders, oppositional defiant disorder, intermittent explosive disorder, conduct disorder, pyromania, kleptomania, paraphilic disorders, medication induced movement disorders, and adverse effects of other medications.

### Claim 22 (depends on 20)

The method of claim 20, wherein the disease or condition is selected from the group consisting of autoimmune diseases, acute pain, chronic pain, neuropathic pain, cancer, cough, infections, tinnitus, hearing loss, loss of taste, loss of smell, endocrine diseases and disorders, diabetes, gastrointestinal tract related diseases, urinary tract diseases, blood diseases, cardiovascular disease, inflammatory diseases, arthritis, paralysis, or spinal cord injury.

### Claim 23

(canceled)

### Claim 24

(canceled)

### Claim 25

(canceled)

### Claim 26 (depends on 20)

The method of claim 20, wherein the subject has taken a hallucinogen.

### Claim 27

(canceled)

### Claim 28

(canceled)

### Claim 29

(canceled)

### Claim 30

(canceled)

### Claim 31

(canceled)
